Drug Profile
Tiotropium bromide - Glenmark Pharmaceuticals
Alternative Names: GSP 304Latest Information Update: 01 Dec 2020
Price :
$50
*
At a glance
- Originator Glenmark Pharmaceuticals Ltd
- Class Antiasthmatics; Antibronchitics; Epoxy compounds; Esters; Small molecules; Thiophenes; Tropanes
- Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 01 Dec 2020 Discontinued - Phase-II for Chronic obstructive pulmonary disease (In the elderly, In adults) in USA (Inhalation) before December 2020
- 31 Jul 2017 Glenmark completes a phase II trial in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (Inhalation) (NCT03118765)
- 24 Mar 2017 Phase-II clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA (Inhalation) (NCT03118765)